This webinar, the ninth and final session of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind natural killer cell engagers. Basic, clinical and translational researchers in academia and industry and members of the investment community are...
01-11-2023 | 10:00 - 12:00 CT
This webinar, the eighth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind therapies involving T cell receptors. Basic, clinical and translational researchers in academia and industry and members of the investment community are the...
12-07-2022 | 14:00 - 16:00 CT
This webinar, the seventh of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind the enhanced blockade of cytotoxic T lymphocyte antigen-4 . Basic, clinical and translational researchers in academia and industry and members of the...
10-05-2022 | 13:00 - 15:00 CT
This webinar, the sixth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind induced pluripotent stem cell-derived cell therapies. Basic, clinical and translational researchers in academia and industry and members of the investment...
09-26-2022 | 10:00 - 12:00 CT
This webinar, the fourth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind the targeted systemic delivery of innate immune activators. Basic, clinical and translational researchers in academia and industry and members of the investment...
08-26-2022 | 10:00 - 12:00 CT
This webinar, the third of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind tumor-infiltrating lymphocyte therapies. Basic, clinical and translational researchers in academia and industry and members of the investment community are the...
07-28-2022 | 12:00 - 14:00 CT
This webinar, the second of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind recombinant IL-18 immunotherapy. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target...
07-18-2022 | 12:00 - 14:00 CT
SITC Congratulates 2022 Election Winners SITC is pleased to share the results of the 2022 SITC Election. The candidates who received the most votes during the election, which took place May 2-13, 2022, are: Newly-Elected SITC Vice President James L. Gulley, MD, PhD, FACP National Cancer...
Guideline News CPG Mobile App The SITC Clinical Practice Guidelines (CPG) Mobile App is the first and only tool of its kind, offering direct, easy, portable access to SITC’s CPGs via phone or tablet. Highlighting key information from SITC’s published guidelines, the SITC CPG Mobile App features...
The Society for Immunotherapy of Cancer (SITC) hosted the 2021 SITC Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, virtually on February 22-24, 2021. Available here are the presentation slides and video from Wednesday, February 24, 2021. Program...
24 attachments
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us